Richard Vines, chairman and chief executive of Rare Cancers Australia, sat down with PharmaDispatch to mark the organisation's four year anniversary, to discuss its creation, achievements and the future.
Richard Vines: Equity should be a reason to fund access, not an excuse to deny it
August 1, 2016 BioPharmaDispatch Executive
Latest Video
New Stories
-
ARCS launches national partnership to boost public clinical research sites
May 27, 2026 - - Latest News -
Australia’s access dilemma and how commercial leaders have adapted over time
May 27, 2026 - - Latest News -
TGA approves Sanofi innovation that offers the chance to delay onset of type 1 diabetes
May 27, 2026 - - Latest News -
This unique historical oddity says all we need to know about the institution
May 26, 2026 - - Latest News -
New Zealand's Pharmac consulting on new vaccine brands and wider flu access for young children
May 26, 2026 - - Latest News -
New national survey reveals muscle health screening gap in Australian general practice
May 26, 2026 - - Latest News -
Mayne Pharma awarded legal costs as business expansion gains momentum
May 25, 2026 - - Latest News
